Does Medicare cover tirzepatide?

Partly: from July 1, 2026 to December 31, 2027, Medicare’s GLP-1 Bridge lets eligible Part D enrollees get Zepbound in the KwikPen, Wegovy or Foundayo for weight management for a $50 copay, subject to BMI criteria, but it does not cover compounded tirzepatide or Zepbound vials. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan might cover a GLP-1 for that condition. Check Medicare.gov for the BMI rules and your plan’s formulary.